DelveInsight’s, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Hepatocellular Carcinoma Pipeline Outlook

 

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

• In September 2024:- Translational Research in Oncology- A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria
• In September 2024:- Hoffmann-La Roche- This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
• In September 2024:- Akeso- The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
• DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
• The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
• Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others

 

Stay informed about the cutting-edge advancements in Hepatocellular Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatocellular Carcinoma Clinical Trials Assessment

 

Hepatocellular Carcinoma Emerging Drugs

 

• Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Liver Cancer and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

• SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

• Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

• Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

• STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various liver cancers. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

 

Learn more about Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatocellular Carcinoma Unmet Needs

 

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Discover the latest advancements in Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

 

Scope of the Hepatocellular Carcinoma Pipeline Report

• Coverage- Global
• Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
• Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
• Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Hepatocellular Carcinoma Pipeline on our website @ Hepatocellular Carcinoma Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Hepatocellular Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Namodenoson: Can-Fite BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SRF388: Surface Oncology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. STP705: Sirnaomics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatocellular Carcinoma Key Companies
21. Hepatocellular Carcinoma Key Products
22. Hepatocellular Carcinoma- Unmet Needs
23. Hepatocellular Carcinoma- Market Drivers and Barriers
24. Hepatocellular Carcinoma- Future Perspectives and Conclusion
25. Hepatocellular Carcinoma Analyst Views
26. Hepatocellular Carcinoma Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/